Purpose: To report institutional outcomes for the use of interstitial\nbrachytherapy for locally advanced cervical cancer.\nMethods and Materials: Retrospective analysis was performed\non patients treated for cervical cancer at the Ohio State University\nWexner Medical Center from 2000 to 2014. A total of 525 patients\nwere identified and 52 of these patients received interstitial\nbrachytherapy and were included in the analysis. All patients\nreceived external beam radiation. All patients were treated with\nlow-dose-rate interstitial brachytherapy, except for one patient who\nwas treated with high-dose-rate interstitial brachytherapy. Actuarial\nestimates of disease free survival, locoregional failure free survival\n(LRFFS), distant metastasis free survival, and overall survival were\ncalculated by Kaplan-Meier.\nResults: At a median OS of 22.1 months for all 52 patients treated\nwith interstitial brachytherapy, LRFFS was 70% at 1 year, 67% at 2\nyears, and 61% at 3 years. Disease free survival at 1, 2, and 3 years\nwere 61%, 52%, and 45%, respectively. Distant metastasis free\nsurvival was 81%, 69%, and 65% at 1, 2, and 3 years, respectively.\nOverall survival was 67% at 1 year, 47% at 2 years, and 30% at 3\nyears. The grade 3 toxicity rate was 9.6% but no grade 4 or higher\ntoxicity occurred.\nConclusion: Interstitial brachytherapy provides good local control\nfor patients with locally advanced cervical cancer with acceptable\ntoxicity. However, local and distant failures are still occurring\ndespite this treatment.
Loading....